The management of acute stroke is now firmly based on evidence from randomised clinical trials. Where possible, a patient should have a CT scan to identify the cause of a stroke. Most strokes are cerebral infarcts. Patients with these ischaemic strokes should be given aspirin. At present, the risks of thrombolytic therapy outweigh the benefits. Surgery may have a role in some patients with carotid stenosis. Primary prevention remains the mainstay in reducing the burden of stroke on Australian society
Each year stroke affects about 40 000 Australians. Approximately one-third die, one-third remain permanently disabled and one-third make a reasonable recovery.1 Stroke accounts for 10% of all deaths and 4% of acute hospital bed utilisation. Information from the Perth Community Stroke Study shows that 80% of strokes are ischaemic, 10% are a primary intracerebral haemorrhage, 5% are a subarachnoid haemorrhage and 5% have an uncertain cause.2 The incidence of stroke rises steeply with increasing age, with 50% of strokes occurring in people more than 75 years of age. Although the overall incidence of stroke is declining, the ageing population will result in a significant increase in elderly stroke patients by the year 2005.
In 1998, the Royal College of Physicians of Edinburgh held a consensus conference on the medical management of stroke, which produced the following statement.
The italicised text in brackets and the references have been added to the consensus statement (shaded text) by Dr Stewart-Wynne.
Royal College of Physicians of Edinburgh
1. The high incidence and serious consequences of stroke make it one of the most important challenges faced by contemporary medicine. In the U.K., stroke is one of the 3 main causes of death and a major cause of long-term disability. As a result, it consumes more National Health Service resources than any other condition.
2. At a conference convened by the Royal College of Physicians of Edinburgh, a consensus panel considered 4 specific issues relating to the medical management of cerebrovascular disease in the U.K. This statement is based on published research, augmented by presentations given at the meeting, and expert opinion.
3. The treatment recommendations in this consensus statement apply only to ischaemic events. Cerebral haemorrhage will need to be excluded before treatment is initiated. Whenever feasible, this should be done as soon as possible with a computed tomography scan.
What is the role of antiplatelet therapy in stroke?
4. The beneficial role of antiplatelet agents in patients with stroke has been clearly established.
5. In acute stroke, aspirin is the only proven antiplatelet agent. It should be commenced as soon as the diagnosis of cerebral infarction has been made, using a starting dose of 150-300 mg a day and continuing until decisions have been made about secondary prevention.
6. In patients with prior ischaemic stroke or transient ischaemic attacks (TIAs), treatment should be with 75-300 mg aspirin, continued long term.
7. There is evidence that clopidogrel (75 mg once daily) and the combination of aspirin and modified-release dipyridamole (200 mg twice daily) are safe and effective alternatives to aspirin alone. There is also some evidence that they may be more effective than aspirin alone, but this evidence does not yet establish sufficient additional benefit to justify their adoption as first-line treatment, particularly in view of their cost. Further randomised controlled trials of both their effectiveness and cost-effectiveness are required.
8. Patients genuinely intolerant of aspirin should be given modified dipyridamole, or clopidogrel when licensed (now available in Australia).
What is the role of anticoagulant therapy in stroke?
9. There is no evidence to support the use of anticoagulants for the treatment of acute stroke, even in patients with atrial fibrillation. Anticoagulation is not associated with an overall reduction in death or disability, as a decrease in recurrent ischaemic stroke is offset by an increase in haemorrhagic stroke. (For every 1000 patients treated, anticoagulants may prevent only one recurrent stroke - 9 fewer recurrent ischaemic strokes, but 8 more haemorrhagic strokes.3) There is also a significant excess of extracranial bleeds. Although there is good evidence that heparin (including low molecular weight heparin) does prevent deep vein thrombosis, the risk of fatal pulmonary embolism is lower than the risk of intracranial haemorrhage in these patients. Physical methods of preventing deep vein thrombosis in stroke patients should therefore be evaluated. Symptomatic venous thromboembolism complicating stroke should be managed according to established guidelines.4
10. Patients who have had a TIA or an ischaemic stroke and are in atrial fibrillation should be considered for long-term treatment with warfarin (suggested target INR 2.5) as this greatly reduces the long-term risk of embolic stroke. If there is a contraindication to warfarin, aspirin should be used. The optimal timing for the initiation of anticoagulation after the acute event is unresolved. In order to minimise the risks of cerebral haemorrhage, the initial treatment should be with aspirin until, for example, the majority of the stroke deficit has resolved or, in the case of more severe strokes, more than two weeks have elapsed. At present, there is no evidence to support the use of warfarin in most patients in sinus rhythm, although there are exceptions such as patients with mechanical heart valves. Warfarin and aspirin should only be given together in exceptional circumstances.
What is the role of thrombolytic therapy in stroke?
11. Intravenous thrombolytic therapy is potentially an effective treatment of acute stroke, offering the possibility of early reperfusion of ischaemic cerebral tissue and limitation of infarct size. However, all thrombolytic drugs need to be given early after the onset of symptoms (probably within 6 hours) and involve a risk of cerebral haemorrhage. There may also be an adverse interaction between streptokinase and aspirin (increased risk of cerebral haemorrhage).
12. Data from 12 randomised controlled trials, involving 3 drugs (streptokinase, urokinase and recombinant tissue plasminogen activator [alteplase]) and fewer than 4000 subjects, are currently available. The results suggest an increase in the proportion of patients making a good recovery by 6 months, but a substantial increase in cerebral haemorrhage within the first two weeks. There are insufficient data available at present to determine the optimal drug and dosage required, although the situation should be clearer within 12 months. (The ECASS II trial has produced a non-significant 3.7% absolute difference between the alteplase and the placebo groups in the proportion with a favourable outcome. However, a post-hoc analysis based on the more commonly used end-point of independence did show a significant benefit of alteplase.5 It is thus not yet proven treatment for acute ischaemic stroke.)
13. Although the potential benefits of thrombolytic therapy are substantial, so too are the risks and the service implications. For this reason, we consider that these drugs whether licensed or unlicensed should not normally be prescribed on present evidence, except in the context of a randomised controlled trial.
14. There is an urgent need for a large, multi centre randomised controlled trial of thrombolytic therapy. This will require extensive organisational changes if adequate numbers of patients are to meet the 6 hour deadline.
What is the role of carotid surgery in stroke?
15. Carotid endarterectomy has a role in preventing stroke in patients with recent (within 6 months) carotid territory symptoms in association with severe stenosis of the ipsilateral carotid artery, and who are fit for surgery. Surgery should be targeted at patients at highest risk of further stroke (such as those with frequent TIAs, cerebral rather than ocular symptoms, ulcerated rather than smooth stenosis) and performed as soon as possible after the initial event. Delays in the process of identifying and investigating patients who might benefit from surgery should be minimised by rapid access to duplex ultrasound, CT and angiography.
16. Surgery should be restricted to specialist centres to minimise peri-operative stroke and deaths; regular audit is essential.
17. Carotid angioplasty with or without stenting may offer an alternative to surgery in selected patients and probably carries similar operative risks. Further randomised controlled trials are essential before this technique comes into routine use, to establish its safety, effectiveness and cost-effectiveness.
18. We emphasise the importance, and urge the further development, of well organised and co-ordinated stroke services. There is good evidence that these lead to improved patient outcomes.6 The elimination of delays in presentation, referral and investigation, and in the initiation of treatment and rehabilitation, are all likely to lead to further improvements.
19. Although 40% of stroke patients are over 80 years of age, few clinical trials have included many patients of this age. We can only suggest extrapolation of trial results to elderly patients, recognising that both the risks and benefits may differ. We also recommend that as many elderly patients as possible should be included in future trials.
20. We have considered the 4 questions we were asked to address. It is also important not to neglect all the other measures which contribute to optimal management, including the detection and effective treatment of hypertension, diabetes mellitus and hyperlipidaemia, and smoking cessation.
21. Stroke patients are particularly vulnerable, and clinicians should bear in mind the legal and ethical reasons for discussing risks, benefits and alternatives with them and, where possible, obtaining valid consent. This is particularly important in the context of clinical trials.
22. Patients with cerebrovascular disease are cared for by a variety of healthcare workers, in both primary and secondary care. We urge these clinicians in each locality to meet to consider these recommendations and incorporate them into their own guidelines and practice.
Post-stroke depression occurs in 23% of patients.7 It should be recognised and treated using an appropriate, well-tolerated antidepressant.
Stroke units have been shown to reduce morbidity and mortality.6 It is likely that the improved outcomes are due to managing simple factors such as prevention of aspiration pneumonia, deep vein thrombosis and urinary tract infections, together with early mobilisation and rehabilitation.
Patients with small non-disabling strokes may certainly be managed in the community, providing that the doctor involved recognises that the stroke is a symptom and not a diagnosis. The cause needs to be investigated (and, if appropriate, treated) and secondary prevention should not be forgotten.
Future research involving trials of thrombolysis, neuroprotective agents, and the new antiplatelet drugs such as the oral glycoprotein IIb/IIIa antagonists may improve the medical management of acute stroke. Primary prevention with attention to risk factors will remain the cornerstone of our attempts to reduce the burden of stroke.
Sharp-eyed readers may have noticed that a familiar name is missing from the credits on the rear cover of this issue. After 15 years of service, Janine Keough has 'retired' from Australian Prescriber.
Janine has not only been responsible for co-ordinating the production of the journal, but has also worked efficiently as the Secretary of the Executive Editorial Board. She has carried out all her duties to a high standard. Her renowned attention to detail has ensured the quality of each issue of the journal.
The Executive Editorial Board of Australian Prescriber expresses its appreciation to Janine and wishes her well in her new endeavours.
The following statements are either true or false.
1. Patients with acute ischaemic strokes should be anticoagulated.
2. Most strokes are ischaemic.
Answers to self-test questions
- Kirsner A, editor. National Stroke Strategy: 1997. Melbourne: National Stroke Foundation; 1997. p. 2.
- Anderson CS, Jamrozik KD, Burvill PW, Chakera TM, Johnson GA, Stewart-Wynne EG. Ascertaining the true incidence of stroke: experience from the Perth Community Stroke Study, 1989-1990. Med J Aust 1993;158:80-4.
- Hankey GJ. Heparin in acute ischaemic stroke. Med J Aust 1998;169:534-6.
- Writing Group for Therapeutic Guidelines: Cardiovascular. Therapeutic guidelines: cardiovascular. 3rd ed. Melbourne: Therapeutic Guidelines Limited; 1999.
- Hacke W, Kasle M, Fieschi C, von-Kummer R, Davalos A, Meier D, et al. Randomised, double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet 1998;352:1245-51.
- Stroke Unit Trialists' Collaboration. Collaborative systematic review of the randomised trials of organised inpatient (stroke unit) care after stroke. Br Med J 1997;314:1151-9.
- Burvill PW, Johnson GA, Jamrozik KD, Anderson CS, Stewart-Wynne EG, Chakera TM. Prevalence of depression after stroke: the Perth Community Stroke Study. Br J Psych 1995;166:320-7.